{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:04Z","timestamp":1794072964283,"version":"4.8.0"},"reference-count":220,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jtha.2023.12.005","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T22:34:51Z","timestamp":1702593291000},"page":"1263-1289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia"],"prefix":"10.1016","volume":"22","author":[{"given":"Glenn F.","family":"Pierce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.12.005_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2023.12.005_bib2","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2023.12.005_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/hae.12000","article-title":"The AIDS epidemic in haemophilia patients II: pursuing absolute viral safety of clotting factor concentrates 1985-1988","volume":"18","author":"Evatt","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/312330a0","article-title":"Expression of active human factor VIII from recombinant DNA clones","volume":"312","author":"Wood","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/312337a0","article-title":"Structure of human factor VIII","volume":"312","author":"Vehar","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/312326a0","article-title":"Characterization of the human factor VIII gene","volume":"312","author":"Gitschier","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/312342a0","article-title":"Molecular cloning of a cDNA encoding human antihaemophilic factor","volume":"312","author":"Toole","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/299178a0","article-title":"Molecular cloning of the gene for human anti-haemophilic factor IX","volume":"299","author":"Choo","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/315683a0","article-title":"Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells","volume":"315","author":"Anson","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.2003.00708.x","article-title":"The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A","volume":"9","author":"Lusher","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib16","doi-asserted-by":"crossref","first-page":"18525","DOI":"10.1073\/pnas.0809677105","article-title":"Antioxidants reduce endoplasmic reticulum stress and improve protein secretion","volume":"105","author":"Malhotra","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.12.005_bib17","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib18","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia\u2013beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.12.005_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene therapy for human genetic disease?","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.jtha.2023.12.005_bib24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hae.14807","article-title":"Towards achieving a haemophilia-free mind","volume":"29","author":"Hermans","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jtha.2023.12.005_bib27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","article-title":"Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles","volume":"20","author":"Chen","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jtha.2023.12.005_bib28","first-page":"164","article-title":"When size matters: FVIII construct optimization leveraging ceDNA, a non-viral gene therapy platform [abstract 333]","volume":"29","author":"Monds","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib29","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.omtn.2022.01.006","article-title":"Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice","volume":"27","author":"Song","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jtha.2023.12.005_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14023","article-title":"Uncertainty in an era of transformative therapy for haemophilia: addressing the unknowns","volume":"27","author":"Pierce","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V95.3.820.003k32_820_828","article-title":"Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector","volume":"95","author":"Balagu\u00e9","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib32","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib36","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib37","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"Roth","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib38","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib39","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2516.2004.00926.x","article-title":"Prospects for gene therapy of haemophilia","volume":"10","author":"Nathwani","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib41","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2023.12.005_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/2040620718791933","article-title":"Gene therapy for hemophilia: what does the future hold?","volume":"9","author":"Doshi","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2023.12.005_bib43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2023.12.005_bib44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib45","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1074\/jbc.273.20.12089","article-title":"Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity","volume":"273","author":"Chang","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.12.005_bib46","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib48","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1182\/blood-2022-166745","volume":"140","author":"Pipe","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib49","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.12.005_bib50","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.12.005_bib51","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib52","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2019-124091","article-title":"Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year","volume":"134","author":"George","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib53","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.12.005_bib55","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib56","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib57","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2021-148651","article-title":"Updated results of the Alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia A","volume":"138","author":"Visweshwar","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib58","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.ymthe.2022.09.020","article-title":"First conditional marketing authorization approval in the European Union for hemophilia \u2018A\u2019 gene therapy","volume":"30","author":"VandenDriessche","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib60","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib61","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib62","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","article-title":"GO-8: preliminary results of a phase I\/II dose escalation trial of gene therapy for haemophilia A using a novel human factor VIII variant","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib63","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2023.12.005_bib64","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/hae.12296","article-title":"Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories","volume":"20","author":"Sommer","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib65","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib66","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtha.2023.12.005_bib67","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib68","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood-2021-150541","article-title":"Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy","volume":"138","author":"Samelson-Jones","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib69","author":"Laffan"},{"key":"10.1016\/j.jtha.2023.12.005_bib70","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib71","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib72","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/j.htct.2023.09.842","article-title":"Bleeding, FVIII activity, and safety 3 years after gene transfer with valoctocogene roxaparvovec: results from GENEr8-1","volume":"45","author":"Mahlangu","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib73","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2022.01.015","article-title":"Treatment-induced hemophilic thrombosis?","volume":"30","author":"Kaczmarek","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib74","first-page":"PB0653","article-title":"52 week efficacy and safety of etranacogene dezaparvovec in adults with severe or moderate-severe hemophilia B: data from the phase 3 HOPE-B gene therapy trial [abstract]","volume":"5","author":"Pipe","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib75","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib76","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1182\/blood-2022-166135","volume":"140","author":"Pipe","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.12412","article-title":"Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII","volume":"12","author":"Shahani","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib78","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtm.2021.12.004","article-title":"Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers","volume":"24","author":"Sihn","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib79","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib80","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2009.280","article-title":"Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus","volume":"18","author":"Hirsch","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib81","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/JVI.80.1.426-439.2006","article-title":"Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype","volume":"80","author":"Grimm","year":"2006","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib82","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1128\/JVI.73.3.1949-1955.1999","article-title":"Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle","volume":"73","author":"Vincent-Lacaze","year":"1999","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib83","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1074\/jbc.M115.687657","article-title":"Chemical modulation of endocytic sorting augments adeno-associated viral transduction","volume":"291","author":"Berry","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.12.005_bib84","doi-asserted-by":"crossref","first-page":"13035","DOI":"10.1128\/JVI.01826-13","article-title":"Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors","volume":"87","author":"Mitchell","year":"2013","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib85","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbrc.2005.03.245","article-title":"Proteasome modulating agents induce rAAV2-mediated transgene expression in human intestinal epithelial cells","volume":"331","author":"Tang","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtha.2023.12.005_bib86","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1128\/JVI.78.6.2863-2874.2004","article-title":"Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia","volume":"78","author":"Yan","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib87","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00251-002-0493-1","article-title":"Viral immune evasion: a masterpiece of evolution","volume":"54","author":"Vossen","year":"2002","journal-title":"Immunogenetics"},{"key":"10.1016\/j.jtha.2023.12.005_bib88","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jtha.2023.12.005_bib89","doi-asserted-by":"crossref","first-page":"veaa043","DOI":"10.1093\/ve\/veaa043","article-title":"Evolution of dependoparvoviruses across geological timescales-implications for design of AAV-based gene therapy vectors","volume":"6","author":"Hildebrandt","year":"2020","journal-title":"Virus Evol"},{"key":"10.1016\/j.jtha.2023.12.005_bib90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0042-6822(70)90248-5","article-title":"The role of herpesviruses in adenovirus-associated virus replication in\u00a0vitro","volume":"42","author":"Atchison","year":"1970","journal-title":"Virology"},{"key":"10.1016\/j.jtha.2023.12.005_bib91","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1128\/JVI.74.8.3494-3504.2000","article-title":"Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein","volume":"74","author":"Ogston","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib92","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41586-023-05949-1","article-title":"Adeno-associated virus type 2 in US children with acute severe hepatitis","volume":"617","author":"Servellita","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib93","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-023-05948-2","article-title":"Adeno-associated virus 2 infection in children with non-A-E hepatitis","volume":"617","author":"Ho","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib94","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib95","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.jtha.2023.12.005_bib96","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jtha.2023.12.005_bib97","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib98","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib99","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1089\/hum.2011.031","article-title":"Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors","volume":"22","author":"Wang","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib100","doi-asserted-by":"crossref","first-page":"15238","DOI":"10.1128\/JVI.79.24.15238-15245.2005","article-title":"Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties","volume":"79","author":"Arbetman","year":"2005","journal-title":"J\u00a0Virol"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.12.005_bib101","article-title":"Prevalence and affinity\/avidity assessment of pre-existing neutralizing antibodies (NAbs) against adeno-associated virus (AAV) vector serotypes 2, 5 and 8 analyzed in the serum of 300 healthy donors [abstract #PB1101]","volume":"4","author":"Majowicz","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NAbs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib103","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib104","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jmv.21360","article-title":"Diverse IgG subclass responses to adeno-associated virus infection and vector administration","volume":"81","author":"Murphy","year":"2009","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2014.00009","article-title":"Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors","volume":"5","author":"Tseng","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.12.005_bib106","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/14712598.2015.1035645","article-title":"Strategies to circumvent humoral immunity to adeno-associated viral vectors","volume":"15","author":"Tse","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib107","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib108","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","article-title":"Advances and challenges for hemophilia gene therapy","volume":"28","author":"Batty","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jtha.2023.12.005_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.753467","article-title":"Adeno-associated viruses (AAV) and host immunity - a race between the hare and the hedgehog","volume":"12","author":"Rapti","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.12.005_bib110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/ijlh.13605","article-title":"Gene therapy for hemophilia: current status and laboratory consequences","volume":"43","author":"Batty","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2023.12.005_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.12.005_bib112","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity \u2013 \u2018one and done\u2019 or \u2018slower and lower\u2019?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib113","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.0105-2896.2006.00393.x","article-title":"Development, trafficking, and function of memory T-cell subsets","volume":"211","author":"Lefran\u00e7ois","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtha.2023.12.005_bib114","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.12.005_bib115","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1126\/science.1058867","article-title":"Preferential localization of effector memory cells in nonlymphoid tissue","volume":"291","author":"Masopust","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jtha.2023.12.005_bib116","first-page":"19","article-title":"Functional assessment of T cell responses to AAV8 empty capsids in healthy volunteers","volume":"30","author":"Schroeder","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib117","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: A long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib118","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.omtm.2019.08.015","article-title":"Clinical considerations for capsid choice in the development of liver-targeted AAV-based gene transfer","volume":"15","author":"Pipe","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib119","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/jvi.63.9.3822-3828.1989","article-title":"Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression","volume":"63","author":"Samulski","year":"1989","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib120","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: tracing the path of AAV transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib121","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib122","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib125","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.ymthe.2022.07.005","article-title":"IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice","volume":"30","author":"Butterfield","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib126","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005082","article-title":"An siRNA screen identifies the U2 snRNP spliceosome as a host restriction factor for recombinant adeno-associated viruses","volume":"11","author":"Schreiber","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jtha.2023.12.005_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007988","article-title":"Ring finger protein 121 is a potent regulator of adeno-associated viral genome transcription","volume":"15","author":"Madigan","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jtha.2023.12.005_bib129","first-page":"A158","article-title":"Investigating mechanisms of variability of AAV5-hFVIII-SQ expression in\u00a0vitro [abstract P501]","volume":"33","author":"Keenan","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-3-030-67696-4_6","article-title":"Defects in protein folding and\/or quality control cause protein aggregation in the endoplasmic reticulum","volume":"59","author":"Poothong","year":"2021","journal-title":"Prog Mol Subcell Biol"},{"key":"10.1016\/j.jtha.2023.12.005_bib131","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/jth.13581","article-title":"Variation in baseline factor VIII concentration in a retrospective cohort of mild\/moderate hemophilia A patients carrying identical F8 mutations","volume":"15","author":"Loomans","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib132","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCULATIONAHA.118.034532","article-title":"Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor VIII and von Willebrand factor plasma levels","volume":"139","author":"Sabater-Lleal","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.12.005_bib133","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hae.14078","article-title":"Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia","volume":"26","author":"Turecek","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib134","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139225","article-title":"AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B confirm stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 5 years","volume":"136","author":"Leebeek","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib136","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1182\/blood-2021-148661","article-title":"First-in-human dose-finding study of AAVhu37 vector-based gene therapy: BAY 2599023 has stable and sustained expression of FVIII over 2 years [abstract]","volume":"138","author":"Pipe","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib137","first-page":"PB0652","article-title":"Evolution of AAV vector gene therapy is ongoing in hemophilia. Will the unique features of BAY 2599023 address the outstanding needs? [abstract]","volume":"5","author":"Pipe","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib138","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1182\/blood-2022-159363","article-title":"AAV8 gene therapy for hemophilia A patients from China","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib139","first-page":"552","article-title":"Stable hemostatic correction and improved hemophilia-related quality of life: final analysis from the pivotal phase 3 HOPE-B trial of etranacogene dezaparvovec [abstract 1192]","volume":"30","author":"Pipe","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib140","doi-asserted-by":"crossref","first-page":"10656","DOI":"10.1182\/blood-2022-163297","article-title":"BAX 335 hemophilia B gene therapy phase 1\/2 clinical trial: long-term safety and efficacy follow-up","volume":"140","author":"Escobar","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003444","article-title":"Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases","volume":"9","author":"Ferreira","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jtha.2023.12.005_bib142","author":"Cuker"},{"key":"10.1016\/j.jtha.2023.12.005_bib143","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/hum.2022.050","article-title":"Human and insect cell-produced recombinant adeno-associated viruses show differences in genome heterogeneity","volume":"33","author":"Tran","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib144","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omtm.2020.05.018","article-title":"Methods matter: standard production platforms for recombinant AAV produce chemically and functionally distinct vectors","volume":"18","author":"Rumachik","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.omtm.2016.12.004","article-title":"Syngeneic AAV pseudo-particles potentiate gene transduction of AAV vectors","volume":"4","author":"Wang","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib146","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1073\/pnas.94.11.5798","article-title":"Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase","volume":"94","author":"Chen","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.12.005_bib147","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ymthe.2005.11.010","article-title":"A\u00a0histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells","volume":"13","author":"Okada","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib148","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.omtm.2022.05.008","article-title":"Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action","volume":"26","author":"Liu","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib149","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2022008948","article-title":"Valoctocogene roxaparvovec gene transfer in participants with HIV","volume":"7","author":"Ragni","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.12.005_bib150","doi-asserted-by":"crossref","first-page":"24451","DOI":"10.1074\/jbc.M111.238758","article-title":"Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response","volume":"286","author":"Brown","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.12.005_bib151","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.omtm.2020.10.013","article-title":"Minimal essential human factor VIII alterations enhance secretion and gene therapy efficiency","volume":"19","author":"Cao","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib152","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-021-01333-6","article-title":"Gene therapy needs a long-term approach","volume":"27","author":"Editorial","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib153","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1111\/hae.13504","article-title":"Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project","volume":"24","author":"Iorio","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib154","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/hae.14131","article-title":"Gene therapy to cure haemophilia: is robust scientific inquiry the missing factor?","volume":"26","author":"Pierce","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib155","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1111\/jth.15023","article-title":"ISTH subcommittee on Factor VIII, Factor IX, rare bleeding disorders. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH","volume":"18","author":"Konkle","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib156","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib157","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1016\/j.ymthe.2022.11.005","article-title":"Transient expression of factor VIII and a chronic high-fat diet induces ER stress and late hepatocyte oncogenesis","volume":"30","author":"Pierce","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib158","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jtha.2023.12.005_bib159","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/mt.2016.17","article-title":"Genotoxicity in mice following AAV gene delivery: a safety concern for human gene therapy?","volume":"24","author":"Chandler","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib160","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2023.12.005_bib161","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nm.3230","article-title":"A\u00a0largely random AAV integration profile after LPLD gene therapy","volume":"19","author":"Kaeppel","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib162","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib163","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ng1179","article-title":"AAV serotype 2 vectors preferentially integrate into active genes in mice","volume":"34","author":"Nakai","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2023.12.005_bib164","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib165","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib166","article-title":"Liver safety case report from the phase 3 HOPE-B gene therapy trial in adults with hemophilia B [abstract]","volume":"5","author":"Schmidt","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib168","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2023.12.005_bib169","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1128\/JVI.01135-13","article-title":"High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration","volume":"87","author":"Janovitz","year":"2013","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib170","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver injury increases the incidence of HCC following AAV gene therapy in mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib171","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib172","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood.2021014735","article-title":"Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A","volume":"140","author":"Batty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib173","first-page":"29","article-title":"Characterisation of adeno-associated virus vector persistence after long-term follow up in the haemophilia A dog model [EAHAD ABS021]","volume":"27","author":"Batty","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib174","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in\u00a0vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib175","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1073\/pnas.0307833100","article-title":"DNA-dependent PK inhibits adeno-associated virus DNA integration","volume":"101","author":"Song","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.12.005_bib176","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/JVI.79.6.3606-3614.2005","article-title":"Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver","volume":"79","author":"Nakai","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtha.2023.12.005_bib177","article-title":"The longitudinal kinetics of AAV5 vector integration profiles in mice","author":"Ismail","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib178","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib179","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ymthe.2006.03.008","article-title":"Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver","volume":"14","author":"Bell","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib180","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/mt.2012.197","article-title":"Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity","volume":"20","author":"Rosas","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib181","doi-asserted-by":"crossref","first-page":"11264","DOI":"10.1073\/pnas.1117032109","article-title":"Induction of hepatocellular carcinoma by in\u00a0vivo gene targeting","volume":"109","author":"Wang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.12.005_bib182","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/mt.2014.240","article-title":"Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates","volume":"23","author":"Walia","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib183","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib184","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ymthe.2005.03.020","article-title":"No evidence for tumorigenesis of AAV vectors in a large-scale study in mice","volume":"12","author":"Bell","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib185","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.omtm.2020.11.015","article-title":"Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors","volume":"20","author":"Ferla","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib186","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib187","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib188","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.36","article-title":"Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery","volume":"1","author":"Brown","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib189","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.omtm.2020.12.006","article-title":"Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning","volume":"20","author":"Nonnenmacher","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib190","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s44161-022-00046-4","article-title":"A\u00a0high-efficiency AAV for endothelial cell transduction throughout the central nervous system","volume":"1","author":"Krolak","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jtha.2023.12.005_bib191","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nbt856","article-title":"Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors","volume":"21","author":"M\u00fcller","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2023.12.005_bib192","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41434-020-00218-6","article-title":"Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor","volume":"30","author":"Barbon","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib193","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/nar\/gkq009","article-title":"Translation efficiency in humans: tissue specificity, global optimization and differences between developmental stages","volume":"38","author":"Waldman","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtha.2023.12.005_bib194","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG motifs in rAAV genomes: avoiding the toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib195","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: the Rubik\u2019s cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib196","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/jmedgenet-2016-104072","article-title":"Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B","volume":"54","author":"Simhadri","year":"2017","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jtha.2023.12.005_bib197","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2023.12.005_bib198","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtha.2023.12.005_bib199","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib200","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1093\/hmg\/ddz148","article-title":"Next-generation AAV vectors-do not judge a virus (only) by its cover","volume":"28","author":"Domenger","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jtha.2023.12.005_bib201","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/biot.201400666","article-title":"Industrial production of clotting factors: challenges of expression, and choice of host cells","volume":"10","author":"Kumar","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.jtha.2023.12.005_bib202","doi-asserted-by":"crossref","first-page":"24121","DOI":"10.1074\/jbc.272.39.24121","article-title":"Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII","volume":"272","author":"Swaroop","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.12.005_bib203","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.94.22.11851","article-title":"Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa","volume":"94","author":"Pipe","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.12.005_bib204","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.2020007562","article-title":"Activated protein C has a regulatory role in factor VIII function","volume":"137","author":"Wilhelm","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89371","article-title":"Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models","volume":"1","author":"Siner","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtha.2023.12.005_bib206","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jtha.2023.04.012","article-title":"Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice","volume":"21","author":"Nguyen","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.005_bib207","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/bloodadvances.2021005758","article-title":"Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII","volume":"6","author":"Vander Kooi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.12.005_bib208","doi-asserted-by":"crossref","first-page":"38345","DOI":"10.1074\/jbc.M206959200","article-title":"High level expression of recombinant porcine coagulation factor VIII","volume":"277","author":"Doering","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.12.005_bib209","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/mt.2008.292","article-title":"Enhanced factor VIII heavy chain for gene therapy of hemophilia A","volume":"17","author":"Chen","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib211","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-08-662916","article-title":"The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity","volume":"127","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib212","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.omtm.2021.04.016","article-title":"Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII","volume":"21","author":"Russell","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib213","first-page":"7","article-title":"CRISPR\/Cas9-mediated targeted insertion of human F9 achieves therapeutic circulating protein levels in mice and non-human primates","volume":"27","author":"Huang","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib214","article-title":"Hemophilia A ameliorated in mice by CRISPR-based in\u00a0vivo genome editing of human factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2023.12.005_bib215","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtha.2023.12.005_bib216","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood-2022-167919","article-title":"Sustained factor VIII activity following single dose of non-viral integrating gene therapy [abstract]","volume":"140","author":"Truong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.005_bib217","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in\u00a0vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100890","article-title":"Hemophilia treatment in 2021: choosing the \u201coptimal\u201d treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians","volume":"52","author":"Hermans","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2023.12.005_bib219","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2147\/PPA.S355627","article-title":"The hemophilia gene therapy patient journey: questions and answers for shared decision-making","volume":"16","author":"Wang","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2023.12.005_bib220","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.12.005_bib221","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13489","article-title":"Past, present and future of haemophilia gene therapy: from vectors and transgenes to known and unknown outcomes","volume":"24","author":"Pierce","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.005_bib223","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","article-title":"High-dose AAV gene therapy deaths","volume":"38","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2023.12.005_bib224","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib225","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.omtm.2022.01.013","article-title":"Characterization of AAV-mediated dorsal root ganglionopathy","volume":"24","author":"Buss","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.12.005_bib226","author":"Chand"},{"key":"10.1016\/j.jtha.2023.12.005_bib228","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.12.005_bib229","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy","volume":"47","author":"Galletta","year":"2022","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jtha.2023.12.005_bib230","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A\u00a0molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623008693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623008693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T02:08:45Z","timestamp":1729217325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623008693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":220,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1538783623008693"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.12.005","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}